Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Issues Suicidality Alert On Antiepileptics

This article was originally published in The Pink Sheet Daily

Executive Summary

A class-wide relabeling is expected, but Pfizer says that Neurontin and Lyrica show no signs of increased events.

You may also be interested in...



Should FDA Drug Safety Alerts Go To Professionals First?

Physicians need to know about drug safety problems before their patients hear about them, Steven Schachter, president of the American Epilepsy Society, told the FDA Transparency Task Force June 24

Should FDA Drug Safety Alerts Go To Professionals First?

Physicians need to know about drug safety problems before their patients hear about them, Steven Schachter, president of the American Epilepsy Society, told the FDA Transparency Task Force June 24

Keppra Gets Six-Month Pediatric Exclusivity

FDA clearance will keep generic versions of the epilepsy drug off the market until Nov. 1.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS066826

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel